Tricyclic urea compounds as JAK2 V617F inhibitors
The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
1. A compound, which is methyl ((1R,3R)-3-(7-(3-fluoro-1-(methyl-d 3 )-1H-pyrazol-4-yl)-8-(4-fluorophenyl)-3-(methyl-d 3 )-2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(2)-yl)cyclopentyl)carbamate, or a pharmaceutically acceptable salt thereof.
2. A compound, which is methyl ((1R,3R)-3-(8-(1,1-dimethyl-1,3-dihydroisobenzofuran-5-yl)-7-(3-fluoro-1-(methyl-d3)-1H-pyrazol-4-yl)-3-(methyl-d3)-2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(2H)-yl)cyclopentyl)carbamate, or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition, comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
4. A pharmaceutical composition, comprising the compound of claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
5. A compound, which is methyl ((1R,3R)-3-(8-(4-fluorophenyl)-7-(3-methoxy-1-methyl-1H-pyrazol-4-yl)-3-methyl-2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(2H)-yl)cyclopentyl)carbamate, or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition, comprising the compound of claim 5 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
7. The compound of claim 1 , which is methyl ((1R,3R)-3-(7-(3-fluoro-1-(methyl-d 3 )-1H-pyrazol-4-yl)-8-(4-fluorophenyl)-3-(methyl-d 3 )-2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(2H)-yl)cyclopentyl)carbamate.
8. A pharmaceutical composition, comprising the compound of claim 7 , and a pharmaceutically acceptable carrier.
9. The compound of claim 2 , which is methyl ((1R,3R)-3-(8-(1,1-dimethyl-1,3-dihydroisobenzofuran-5-yl)-7-(3-fluoro-1-(methyl-d3)-1H-pyrazol-4-yl)-3-(methyl-d3)-2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(2H)-yl)cyclopentyl)carbamate.
10. A pharmaceutical composition, comprising the compound of claim 9 , and a pharmaceutically acceptable carrier.
11. The compound of claim 5 , which is methyl ((1R,3R)-3-(8-(4-fluorophenyl)-7-(3-methoxy-1-methyl-1H-pyrazol-4-yl)-3-methyl-2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(2H)-yl)cyclopentyl)carbamate.
12. A pharmaceutical composition, comprising the compound of claim 11 , and a pharmaceutically acceptable carrier.